Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort

The spectrum of antinuclear antibodies (ANAs) is changing to include both nuclear staining as well as cytoplasmic and mitotic cell patterns (CMPs) and accordingly a change is occurring in terminology to anticellular antibodies. This study examined the prevalence of indirect immunofluorescence (IIF) anticellular antibody staining using the Systemic Lupus International Collaborating Clinics inception cohort.

[1]  Matthias Schneider,et al.  Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta‐Regression of Diagnostic Data , 2018, Arthritis care & research.

[2]  P. Lipsky,et al.  Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE , 2018, Annals of the rheumatic diseases.

[3]  Y. Shoenfeld,et al.  Predictive autoimmunity using autoantibodies: screening for anti-nuclear antibodies , 2017, Clinical chemistry and laboratory medicine.

[4]  D. Pisetsky.  Antinuclear antibody testing — misunderstood or misbegotten? , 2017, Nature Reviews Rheumatology.

[5]  I. Bruce,et al.  The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients , 2017, Lupus.

[6]  Melissa Zhao.  ANA-Negative Presentation of SLE in Man with Severe Autoimmune Neutropenia , 2016, Case reports in medicine.

[7]  Paulo Luiz Carvalho Francescantônio,et al.  Report on the second International Consensus on ANA Pattern (ICAP) workshop in Dresden 2015 , 2016, Lupus.

[8]  M. Fritzler,et al.  Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care , 2016, Lupus.

[9]  M. Fritzler.  Choosing wisely: Review and commentary on anti-nuclear antibody (ANA) testing. , 2016, Autoimmunity reviews.

[10]  Caroline Gordon,et al.  The frequency and outcome of lupus nephritis: results from an international inception cohort study. , 2016, Rheumatology.

[11]  T. Mimori,et al.  International consensus on ANA patterns (ICAP): the bumpy road towards a consensus on reporting ANA results , 2016, Autoimmunity Highlights.

[12]  M. Keddis,et al.  Antinuclear Antibody-Negative Lupus Nephritis with Full House Nephropathy: A Case Report and Review of the Literature , 2016, American Journal of Nephrology.

[13]  G. Tan,et al.  The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis , 2015, Lupus.

[14]  I. Bruce,et al.  American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort , 2014, The Journal of Rheumatology.

[15]  M. Fritzler,et al.  Current Concepts and Future Directions for the Assessment of Autoantibodies to Cellular Antigens Referred to as Anti-Nuclear Antibodies , 2014, Journal of immunology research.

[16]  L. Truedsson,et al.  Clinical phenotype associations with various types of anti-dsDNA antibodies in patients with recent onset of rheumatic symptoms. Results from a multicentre observational study , 2014, Lupus Science & Medicine.

[17]  Renata Baronaite,et al.  A Comparison of Anti-Nuclear Antibody Quantification Using Automated Enzyme Immunoassays and Immunofluorescence Assays , 2014, Autoimmune diseases.

[18]  Torsten Witte,et al.  International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies , 2013, Annals of the rheumatic diseases.

[19]  L. Truedsson,et al.  Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study , 2013, Scandinavian journal of rheumatology.

[20]  Jun Liu,et al.  Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. , 2013, Arthritis and rheumatism.

[21]  D. Beirness,et al.  The basis for Canada's new low-risk drinking guidelines: a relative risk approach to estimating hazardous levels and patterns of alcohol use. , 2012, Drug and alcohol review.

[22]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[23]  D. Gladman,et al.  The Systemic Lupus International Collaborating Clinics (SLICC) group – It was 20 years ago today , 2011, Lupus.

[24]  M. Fritzler,et al.  Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies , 2008, Arthritis research & therapy.

[25]  A. Bengtsson,et al.  Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[26]  M. Bokarewa,et al.  Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. , 2008, The Journal of rheumatology.

[27]  I. Bruce,et al.  Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. , 2008, Arthritis and rheumatism.

[28]  J. Reveille,et al.  A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. , 2007, Arthritis and rheumatism.

[29]  K. Kessenbrock,et al.  International Multicenter Evaluation of Autoantibodies to Ribosomal P Proteins , 2006, Clinical and Vaccine Immunology.

[30]  L. Cross,et al.  Antinuclear antibody-negative lupus as a distinct diagnostic entity--does it no longer exist? , 2004, QJM : monthly journal of the Association of Physicians.

[31]  J. B. Rattner,et al.  Autoantibodies to components of the mitotic apparatus , 1998, Molecular Biology Reports.

[32]  E. Chan,et al.  Autoantibodies to protein transport and messenger RNA processing pathways: endosomes, lysosomes, Golgi complex, proteasomes, assemblyosomes, exosomes, and GW bodies. , 2004, Clinical immunology.

[33]  K. Kessenbrock,et al.  Technical and clinical evaluation of anti‐ribosomal P protein immunoassays , 2004, Journal of clinical laboratory analysis.

[34]  M. Fritzler,et al.  Specificity of autoantibodies to SS‐A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate , 2002, Journal of clinical laboratory analysis.

[35]  N. Blanckaert,et al.  Screening for autoantibodies to SS-A/Ro by indirect immunofluorescence using HEp-2000TM cells , 2000, Annals of clinical biochemistry.

[36]  M. Reichlin.  ANA negative systemic lupus erythematosus sera revisited serologically , 2000, Lupus.

[37]  I. Peene,et al.  Sensitivity of the HEp-2000 Substrate for the Detection of Anti-SSA/Ro60 Antibodies , 2000, Clinical Rheumatology.

[38]  Morris Cn,et al.  Antinuclear antibody negative lupus associated with dystrophic calcification. , 1998 .

[39]  J. B. Rattner,et al.  Autoantibodies to a group of centrosomal proteins in human autoimmune sera reactive with the centrosome. , 1998, Arthritis and rheumatism.

[40]  E. Matteson,et al.  Antinuclear antibody negative lupus associated with dystrophic calcification. , 1998, The Journal of rheumatology.

[41]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[42]  J. Koziol,et al.  Range of antinuclear antibodies in "healthy" individuals. , 1997, Arthritis and rheumatism.

[43]  J. McCluskey,et al.  Rapid And Sensitive Detection Of Anti‐Ro (Ss‐A) Antibodies By Indirect Immunofluorescence Of 60Kda Ro Hep‐2 Transfectants , 1996, Pathology.

[44]  D. Isenberg,et al.  SLE: a rheumatological view. Analysis of the clinical features, serology and immunogenetics of 100 SLE patients during long-term follow-up. , 1990, The Quarterly journal of medicine.

[45]  R. Weisbart,et al.  Effect of corticosteroids on serum antinuclear antibodies in man. , 1984, Immunopharmacology.

[46]  P. Stastny,et al.  Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. , 1982, Annals of internal medicine.

[47]  M. Reichlin,et al.  Serological findings in patients with "ANA-negative" systemic lupus erythematosus. , 1981, Medicine.

[48]  M. Wood,et al.  Analysis and interpretation of data. , 1978, The Journal of family practice.

[49]  D. Gladman,et al.  Systemic lupus erythematosus with negative LE cells and antinuclear factor. , 1978, The Journal of rheumatology.

[50]  P. Lundberg,et al.  S.L.E. NEPHRITIS WITH POSITIVE TESTS FOR ANTIBODIES AGAINST NATIVE D.N.A. BUT NEGATIVE TESTS FOR ANTINUCLEAR ANTIBODIES , 1977, The Lancet.

[51]  J. Condemi,et al.  ANTINUCLEAR FACTORS IN SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS. , 1965, Annals of internal medicine.